Abbott receives fda approval for triclip™, first-of-its-kind device to repair leaky tricuspid heart valve

Triclip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery more than 1.6 million people in the u.s. are affected by tricuspid regurgitation,1 which can severely impact quality of life data from the triluminate™ pivotal trial demonstrated that patients who received triclip experienced a marked improvement in the severity of their symptoms and quality of life, with benefits sustained at one year abbott park, ill., april 2, 2024 /prnewswire/ -- abbott (nyse: abt) today announced that the u.s. food and drug administration (fda) has approved the company's first-of-its-kind triclip™ transcatheter edge-to-edge repair (teer) system that's specifically designed for the treatment of tricuspid regurgitation (tr), or a leaky tricuspid valve.
ABT Ratings Summary
ABT Quant Ranking